Align Financial’s Edwards Lifesciences EW Stock Holding History

Align Financial’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$777	Buy	+9	New	+$800	﹤0.01%	427

Other funds holding EW

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Ninety One Cape Town, South Africa $2B AUM 34.6% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Align Financial's EW Position: Q3 2026 in Review

Align Financial opened a new position in Edwards Lifesciences (EW) in Q3 2026: 9 shares worth $777. The stake represents ﹤0.01% of the portfolio and ranks #427 among its holdings.

242 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Align Financial held 9 shares of Edwards Lifesciences worth $777 as of Q3 2026.
Edwards Lifesciences was a new Align Financial position in Q3 2026.
Edwards Lifesciences made up ﹤0.01% of Align Financial's portfolio in Q3 2026, its #427 holding.
242 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Align Financial's 13F filing for Q3 2026, filed 16 Oct 2026.